-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professional reading reference only
To standardize the use of sequential therapy, the timing of switching TKIs is a key point
The significant clinical benefit of the first-line sequential treatment mode of crizotinib has been fully confirmed by clinical studies and real-world experience, successfully setting a new benchmark for 7-year long-term survival for ALK-positive advanced NSCLC, and the continuous development of targeted drugs It is also expected to further prolong survival
Reference: [1].
*This article is only used to provide scientific information to medical professionals and does not represent the views of this platform